Introduction
InPHARM was founded in 2002 and currently acts both in the Czech Republic and the Slovak Republic, with representative offices in Prague and Bratislava.
The main strategy of the company is based on the representation of high quality products for medicinal and pharmaceutical market. The product portfolio consists mainly of OTC drugs, food supplements, and medical devices. The priority for the introduction to the pharmaceutical market is always the efficacy and the safety of the particular product, proven according to the evidence-based medicine (clinical studies, case reports, etc.). The products have to fulfill strong requirements on the pharmaceutical documentation enabling the warranty of the declared product quality.
InPHARM integrates experts from medicine, pharmacy and marketing, and through their cooperation creates qualified marketing services supporting the appropriate use and sales of the particular product.
All activities considering the new product start always with the product registration, objective setting of the communication both to medical experts and general public, and the distribution solely through pharmacies. The very important feature of the company strategy is the integration of all available information to a clinical context. This is the only way to ensure appropriate use of the product by medical professionals and general public.
InPHARM is active mainly in the following therapeutic areas: allergy and respiratory diseases, dermatology, immunology, nervous system, sleeping disorders, urovaginal infections etc. The company communicates mainly through the pediatricians, general practitioners, allergologists and pharmacists. As the main success of InPHARM the introduction of Imunoglukan into the therapeutic praxis of pediatricians may be considered. Nevertheless, also the other products (Sinomarin, Enterina, Saframyl, Probacin, Candilac, Gengigel) may be considered as really outstanding, thanks to their unique active substance, drug form or technology.
The very special project of inPHARM is the cooperation with the University of Camerino (Italy). The key point of the cooperation is research and development of the probiotic culture SYNBIOTEC and it\\'s use in medicine, pharmacy, or food industry (functional food). Probiotic culture SYNBIOTEC is the result of the years of research at the University of Camerino and exhibits very unique qualitative properties among probiotics.
